ABL 001 - ABL BioAlternative Names: ABL001 - ABL Bio
Latest Information Update: 11 Mar 2017
At a glance
- Originator ABL Bio
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action DLL4 protein inhibitors; Vascular endothelial growth factors inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 09 Mar 2017 ABL Bio intends to file an IND application with the US FDA for Solid tumours in 2Q 2017
- 09 Mar 2017 ABL Bio plans a phase I trial for Solid tumours